ET Healthcare Files for IPO Following Continued Backing from Matrix Partners China

VCBeat (WeChat ID: vcbeat) has learned that Singlera Genomics has announced the completion of a new round of financing. The funds will support Singlera’s expansion into domestic and international markets and accelerate the development of new products. Singlera Genomics is a company specializing in innovative immune diagnostic platform systems. Max Star Ventures first invested in Singlera Genomics in 2015 and has continued to increase its investment over the past few years.

In recent years, Xingtong Medical has achieved rapid development in China’s immunodiagnostic market, with its sales channels covering most provinces and municipalities across the country. The Pylon 3D fully automated immunoassay analyzer, featuring world-leading technology, has been installed and put into use in the clinical laboratories of hundreds of large and medium-sized hospitals. The performance and quality of Xingtong’s reagents for procalcitonin (PCT), B-type natriuretic peptide (BNP), and cardiac troponin I (cTnI) are comparable to those of major international brands.

Following ISO 13485 quality management system certification, StarrySky Medical’s instruments and reagents have obtained CE marking, opening the door to international markets. Additionally, StarrySky is actively preparing to apply for U.S. FDA marketing authorization, aiming to enter the U.S. market as soon as possible.

To date, Xingtong Medical has secured nearly 50 invention patents in the United States, China, Europe, Japan, and other regions, establishing a robust intellectual property protection barrier for its core technologies.

Li Xin, Managing Director at Maxing Investment, stated: “We have accompanied the company through years of growth and deeply resonate with the vision and original aspirations of CEO Dr. Tan Hongbo. Throughout this journey, we have witnessed the company’s steady business progress and remarkable achievements, which are particularly valuable given the complex environment of China’s IVD market. It is precisely these unique values that have motivated Maxing Investment to continue investing in Singlera.”

Dr. Tan Hong, CEO of Singlera Genomics, stated, “At a time when investment trends are shifting, I am deeply grateful to both new and existing investors for their trust and support in Singlera. This also demonstrates that the capital market recognizes the achievements made by Singlera and affirms the strength of our team. We will continue to strive tirelessly to establish Singlera as a world-leading diagnostic technology company.”